News headlines about Zimmer Biomet (NYSE:ZBH) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zimmer Biomet earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.5230073075334 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern’s rankings:
- Keep Eye on 52-week Low Price – Zimmer Biomet Holdings, Inc. (ZBH) – The Stocks News (press release) (thestocksnews.com)
- Hot Tickers: Zimmer Biomet Holdings, Inc. (ZBH), Crocs, Inc. (CROX) – Market Movers (financialqz.com)
- Equities Analysts Offer Predictions for Zimmer Biomet Holdings Inc’s FY2017 Earnings (ZBH) (americanbankingnews.com)
- FDA Nod for Zimmer Biomet’s Sidus, Aids Arthroplasty Arm (zacks.com)
- FDA Nod for Zimmer Biomet's Sidus, Aids Arthroplasty Arm (finance.yahoo.com)
A number of research analysts have issued reports on the stock. Canaccord Genuity reissued a “hold” rating and set a $132.00 target price on shares of Zimmer Biomet in a research note on Friday, January 5th. Cantor Fitzgerald reissued an “overweight” rating on shares of Zimmer Biomet in a research note on Friday, January 5th. SunTrust Banks reissued a “buy” rating and set a $136.00 target price on shares of Zimmer Biomet in a research note on Monday, October 2nd. Morgan Stanley reduced their target price on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating for the company in a research note on Thursday, November 2nd. Finally, Stifel Nicolaus reissued a “hold” rating and set a $120.00 target price on shares of Zimmer Biomet in a research note on Friday, November 3rd. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, fifteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Zimmer Biomet presently has an average rating of “Buy” and an average price target of $137.42.
Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). Zimmer Biomet had a return on equity of 3.82% and a net margin of 5.43%. The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter last year, the firm posted $1.79 earnings per share. The firm’s quarterly revenue was down .8% compared to the same quarter last year. sell-side analysts anticipate that Zimmer Biomet will post 8.03 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Monday, January 29th. Investors of record on Friday, December 29th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, December 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.78%. Zimmer Biomet’s payout ratio is currently 29.91%.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by BBNS and is owned by of BBNS. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://baseballnewssource.com/markets/zimmer-biomet-zbh-earning-somewhat-positive-media-coverage-report-finds/1823809.html.
Zimmer Biomet Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with our FREE daily email newsletter.